Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Takes Focused Approach In Bid To Deliver Decentralized Clinical Trials Guide By Year End

Executive Summary

EU regulators are eager to roll out harmonized requirements for decentralized clinical trials by the end of 2022 and so have decided to tackle some of the notably trickier issues in greater detail later on.

You may also be interested in...

EU Aims To Drive Uptake In Decentralized Clinical Trials With Harmonized Guide

The highly anticipated pan-EU recommendation paper on decentralized clinical trials explains the factors that sponsors should consider when designing and implementing such trials.

Decentralized Trial Approaches: How Do They Match Up To Conventional Studies?

Mira Zuidgeest is the principal investigator of a key EU study that proposes to compare fully remote, hybrid and conventional clinical trial approaches. She talks to the Pink Sheet about how the study might help understand “where we're heading with decentralized clinical trials.” 

EU Guidance To Tackle Sponsor/Investigator Overlap In Decentralized Trials

With sponsors of decentralized clinical trials increasingly getting involved in contracting third-party vendors to deliver services that are traditionally overseen by investigators, a much-awaited EU recommendation paper will explain how both parties can maintain control over their distinctive roles.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts